Glaucoma is a progressive disease of the optic nerve, caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in the United States. Glaucoma treatment aims to…
Glaucoma is a progressive disease of the optic nerve, caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in the United States. Glaucoma treatment aims to…
In the last decade, the biosimilar therapy market has been growing, led mainly by two therapeutic areas: immunology and oncology. It now continues to expand into new fields. To enhance this growth…
In 2019, Amgen / Allergan's trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
In the last decade, the biosimilar therapy market has been growing, led mainly by two therapeutic areas: immunology and oncology. It now continues to expand into new fields. To enhance this growth…
Chronic kidney disease (CKD) refers to a set of heterogenous disorders that affect the structure and function of the kidneys. The CKD drug market comprises a wide variety of antihypertensive agents…
Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…
asdfasdf
Immune checkpoint inhibitors have greatly altered the treatment landscape for urothelial carcinoma. Initially confined to advanced disease, the anti-PD-1 therapies Keytruda (Merck & Co.) and Opdivo…
The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…
The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…
Immune checkpoint inhibitors, such as Merck & Co.’s Keytruda and GlaxoSmithKline’s Jemperli, and targeted therapies, such as Eisai’s Lenvima, have revolutionized the therapeutic landscape of…
Immune checkpoint inhibitors, such as Merck & Co.’s Keytruda and GlaxoSmithKline’s Jemperli, and targeted therapies, such as Eisai’s Lenvima, have revolutionized the therapeutic landscape of…